The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients

Bun Hee Lee, Yong Ku Kim

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Hyperprolactinemia can be induced by dopamine D2 receptor-binding drugs such as antipsychotic drugs. The author investigated the relationship between changes in prolactin (PRL) and clinical efficacy of risperidone. In this study, 27 acute psychotic inpatients completed a 12-week trial of risperidone. At baseline and at 2, 4, 8, and 12 weeks after beginning medication, the author measured PRL, assessed hyperprolactinemia-related symptoms, and administered the Brief Psychotic Rating Scale (BPRS). Risperidone treatment significantly elevated serum PRL level (range: 26.9 ng/ml-320.0 ng/ml). The increases of PRL in females were higher than males. The changes in serum PRL levels were not significantly correlated with the improvements in total BPRS scores. PRL-related symptoms such as irregular menstruation, galactorrhea, or erectile dysfunction occurred in nine subjects (7 females and 2 males) whose serum PRL levels increase very highly after 2 weeks of risperidone. In conclusion, our study suggests that the changes in serum PRL levels were not significantly correlated with clinical efficacy of risperidone.

Original languageEnglish
Pages (from-to)658-662
Number of pages5
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume30
Issue number4
DOIs
Publication statusPublished - 2006 Jun 1

Fingerprint

Risperidone
Prolactin
Inpatients
Hyperprolactinemia
Serum
Galactorrhea
Menstruation
Dopamine D2 Receptors
Erectile Dysfunction
Antipsychotic Agents

Keywords

  • Clinical efficacy
  • Prolactin
  • Risperidone
  • Schizoaffective disorder
  • Schizophrenia

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

@article{ff0adbdd582e4b21aee040ee5bdeca9d,
title = "The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients",
abstract = "Hyperprolactinemia can be induced by dopamine D2 receptor-binding drugs such as antipsychotic drugs. The author investigated the relationship between changes in prolactin (PRL) and clinical efficacy of risperidone. In this study, 27 acute psychotic inpatients completed a 12-week trial of risperidone. At baseline and at 2, 4, 8, and 12 weeks after beginning medication, the author measured PRL, assessed hyperprolactinemia-related symptoms, and administered the Brief Psychotic Rating Scale (BPRS). Risperidone treatment significantly elevated serum PRL level (range: 26.9 ng/ml-320.0 ng/ml). The increases of PRL in females were higher than males. The changes in serum PRL levels were not significantly correlated with the improvements in total BPRS scores. PRL-related symptoms such as irregular menstruation, galactorrhea, or erectile dysfunction occurred in nine subjects (7 females and 2 males) whose serum PRL levels increase very highly after 2 weeks of risperidone. In conclusion, our study suggests that the changes in serum PRL levels were not significantly correlated with clinical efficacy of risperidone.",
keywords = "Clinical efficacy, Prolactin, Risperidone, Schizoaffective disorder, Schizophrenia",
author = "Lee, {Bun Hee} and Kim, {Yong Ku}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.pnpbp.2005.11.037",
language = "English",
volume = "30",
pages = "658--662",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients

AU - Lee, Bun Hee

AU - Kim, Yong Ku

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Hyperprolactinemia can be induced by dopamine D2 receptor-binding drugs such as antipsychotic drugs. The author investigated the relationship between changes in prolactin (PRL) and clinical efficacy of risperidone. In this study, 27 acute psychotic inpatients completed a 12-week trial of risperidone. At baseline and at 2, 4, 8, and 12 weeks after beginning medication, the author measured PRL, assessed hyperprolactinemia-related symptoms, and administered the Brief Psychotic Rating Scale (BPRS). Risperidone treatment significantly elevated serum PRL level (range: 26.9 ng/ml-320.0 ng/ml). The increases of PRL in females were higher than males. The changes in serum PRL levels were not significantly correlated with the improvements in total BPRS scores. PRL-related symptoms such as irregular menstruation, galactorrhea, or erectile dysfunction occurred in nine subjects (7 females and 2 males) whose serum PRL levels increase very highly after 2 weeks of risperidone. In conclusion, our study suggests that the changes in serum PRL levels were not significantly correlated with clinical efficacy of risperidone.

AB - Hyperprolactinemia can be induced by dopamine D2 receptor-binding drugs such as antipsychotic drugs. The author investigated the relationship between changes in prolactin (PRL) and clinical efficacy of risperidone. In this study, 27 acute psychotic inpatients completed a 12-week trial of risperidone. At baseline and at 2, 4, 8, and 12 weeks after beginning medication, the author measured PRL, assessed hyperprolactinemia-related symptoms, and administered the Brief Psychotic Rating Scale (BPRS). Risperidone treatment significantly elevated serum PRL level (range: 26.9 ng/ml-320.0 ng/ml). The increases of PRL in females were higher than males. The changes in serum PRL levels were not significantly correlated with the improvements in total BPRS scores. PRL-related symptoms such as irregular menstruation, galactorrhea, or erectile dysfunction occurred in nine subjects (7 females and 2 males) whose serum PRL levels increase very highly after 2 weeks of risperidone. In conclusion, our study suggests that the changes in serum PRL levels were not significantly correlated with clinical efficacy of risperidone.

KW - Clinical efficacy

KW - Prolactin

KW - Risperidone

KW - Schizoaffective disorder

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=33646103894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646103894&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2005.11.037

DO - 10.1016/j.pnpbp.2005.11.037

M3 - Article

C2 - 16466670

AN - SCOPUS:33646103894

VL - 30

SP - 658

EP - 662

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 4

ER -